Zacks Research Has Negative Outlook of CPRX FY2025 Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities researchers at Zacks Research reduced their FY2025 earnings estimates for Catalyst Pharmaceuticals in a research report issued on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of $2.02 for the year, down from their prior estimate of $2.07. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ FY2026 earnings at $2.25 EPS and FY2027 earnings at $2.37 EPS.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Bank of America reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Stephens reissued an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $24.23 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $14.47 and a fifty-two week high of $24.64. The company has a 50 day simple moving average of $22.39 and a two-hundred day simple moving average of $21.63. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of 20.53, a P/E/G ratio of 3.31 and a beta of 0.84.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Summit Investment Advisors Inc. grew its holdings in Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 580 shares during the period. Bank of Montreal Can grew its stake in shares of Catalyst Pharmaceuticals by 6.2% during the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 875 shares during the period. Rhumbline Advisers increased its holdings in Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock worth $6,518,000 after acquiring an additional 952 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock valued at $740,000 after purchasing an additional 1,000 shares in the last quarter. Finally, PDT Partners LLC increased its stake in Catalyst Pharmaceuticals by 5.2% in the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock worth $431,000 after buying an additional 1,030 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.